Phase 3 N=48 Major Depressive Disorder With Mixed Features - Extension
Major Depressive Disorder
Primary: Percentage of Subjects With Treatment Emergent Adverse Events (TEAEs) — 66.7 percentage of subjects
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=211 Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose
Major Depressive Disorder With Mixed Features
Primary: Mean Change From Baseline to the 6-week Study Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Scores — -20.5; -13.0 units on a scale — p=<0.0001
Phase 4 N=126 Sustaining Remission of Psychotic Depression
Psychotic Depression
Primary: Number of Subjects at Risk of Relapse During the Randomized Phase. — 13; 34 Participants
Phase 2 N=97 Assessing Symptomatic Clinical Episodes in Depression
Major Depressive Disorder
Primary: MADRS Score - Overall Change From Baseline — 13.7; 8.8 score on a scale — p=<.001
Phase 3 N=1,149 A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder
Major Depressive Disorder
Primary: Phase C: Time-to-Relapse by Any Criteria as Defined in Blinded Addendum — 63.0; 63.0 days — p=0.5100
N/A N=205 Depression Attention for Women Now (The DAWN Study)
Depressive Disorder
Primary: Depression Treatment Outcome — 0.96; 1.33 units on a scale
Phase 3 N=488 Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder
Bipolar Depression · Major Depressive Disorder
Primary: Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score — -18.1; -12.4 score on a scale — p=<0.0001
Phase 4 N=21 Brexpiprazole for Bipolar Depression
Bipolar Depression
Primary: The Montgomery-Asberg Depression Rating Scale (MADRS) — 31.95; 9.95; 10.95 score on a scale — p=<.001
Phase 3 N=259 Study of Pharmacotherapy of Psychotic Depression
Major Depressive Disorder With Psychotic Features
Primary: Remission of Depression Hamilton Depression Scale (Ham-D) and Psychosis Schedule for Affective Disorders in Schizophrenia - Delusional Item (SADS) During the Course of…
Phase 3 N=16 The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression
Psychotic Depression
Primary: Depression and Psychosis Response Rate — 62.5 percent of participants
Phase 3 N=298 Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
Adjunctive Treatment of Major Depressive Disorder
Primary: Change From Baseline to Week 5 in Hamilton Depression Scale (17 Items) (HAMD-17) Total Score — -9.0; -8.1 score on a scale — p=0.2956
N/A N=100 Psychosis: Early Detection, Intervention and Prevention
Prodromal Schizophrenia · Psychotic Disorders · Severe Bipolar Disorder With Psychotic Features
Primary: Onset of Psychosis — 10; 14 percentage of sample converting
Phase 3 N=327 A Trial of AXS-05 in Patients With Major Depressive Disorder
Depression · Major Depressive Disorder
Primary: Change in MADRS Total Score From Baseline to Week 6 — 15.91; 12.04 score on a scale — p=0.002
Phase 2 N=207 Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)
Adjunctive Treatment of Major Depressive Disorder
Primary: Change From Baseline to Week 5 in the HAMD-17 Total Score — 22.9; 22.0; 20.3; 20.4 score on a scale — p=0.0390
Phase 4 N=49 Predictors of Response to Augmentation With Ziprasidone (Geodon®) in Major Depressive Disorder
Depression · Bipolar Disorder
Primary: MADRS Improvement Over 6 Weeks — 10.0; 6.7 units on a scale — p=0.48
Phase 3 N=480 Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Major Depressive Disorder
Primary: Montgomery-Asberg Depression Rating Scale — -14.7; -10.2 units on a scale — p=<0.0001
Phase 2 N=819 Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
Major Depressive Disorder
Primary: Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at Week 8 — -12.5; -13.4; -14.6 Units on a scale — p=0.2404
Phase 2 N=12 Pramipexole to Target "Anhedonic Depression"
Depression, Bipolar · Depression, Unipolar · Dysthymia
Primary: Dimensional Anhedonia Rating Scale (DARS) Score — 15.75; 33.08 score on a scale
Phase 3 N=349 A Study of Aripiprazole in Patients With Major Depressive Disorder
Major Depressive Disorder
Primary: Mean Change in the Montgomery Åsberg Depression Rating Scale (MADRS) — -10.12; -6.39 units on a scale — p=<0.001
Phase 2 N=27 Effects of Psilocybin in Major Depressive Disorder
Major Depressive Disorder
Primary: The GRID-Hamilton Depression Rating Scale (GRID-HAMD) — 22.9; 22.5; NA; 23.8 units on a scale
Phase 4 N=122 Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder
Major Depressive Disorder
Primary: Change From Baseline in IDS-SR-10 Engagement — -8.11 score on a scale — p=<0.0001
Phase 4 N=32 12- Week Open Label Treatment of Refractory Bipolar Depression
Bipolar Disorder
Primary: Primary Measure:Reduction in Depression Symptoms — 16 participants
Phase 3 N=824 Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)
Depressive Disorder · Depression · Depressive Disorder, Major
Primary: Change From Baseline (End of Phase A [Week 8]) to Week 14 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score for the Efficacy Sample. — -8.27; -5.15 Units…
Phase 2 N=1,197 SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Major Depressive Disorder
Primary: Change in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Total Score From Augmentation Baseline (Week 8) to Week 16 (Double-blind Phase, Dose Response Evaluable Set)…
Phase 4 N=60 Low Dose Amisulpride Vs Olanzapine-Fluoxetine Combination in Post-Schizophrenic Depression
Post-Schizophrenic Depression
Primary: Calgary Depression Scale for Schizophrenia (CDSS) — 8.31; 8.62 score on a scale
Phase 3 N=225 A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy
Major Depressive Disorder
Primary: MADRS (Montgomery-Asberg Depression Rating Scale) Response Rate — 10; 11; 29; 5 Participants
Phase 3 N=484 Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Major Depressive Disorder
Primary: Montgomery-Åsberg Depression Rating Scale — -14.7; -9.8 score on a scale — p=<0.0001
Phase 2 N=39 Lexapro and Pramipexole and to Treat Major Depression
Major Depression
Primary: Montgomery Asberg Depression Rating Scale (MADRS) — 22.629; 26.102; 29.455 Score on a scale — p=.018
Phase 2 N=204 Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs Placebo
Major Depressive Disorder
Primary: Change From Baseline in Hamilton Depression Rating Scale (HAMD-17) Total Score at Weeks 8 — -9.0; -7.4 Scores on a scale — p=0.121
Phase 3 N=586 Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder
Major Depressive Disorder
Primary: Mean Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -9.6; -10.5; -7.4 Rating score — p=0.006